Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q3 EPS of ($0.23), $0.16 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.